Skip to main content
Explore URMC

URMC Logo

menu

Open Studies

Our studies are sponsored by the National Cancer Institute (NCI) and affiliated national cooperative research groups, industry, and individual principal investigators (PI).

Study Locations

  • SMH: Strong Memorial Hospital
  • HH: Highland Hospital
  • PR: Cancer Center at Park Ridge
  • Sands: Sands Cancer Center
  • Pluta: Pluta Cancer Center

 

SITE SPONSOR LOCAL # LOCATION(S) OPEN STUDY TITLE
Any NRG ARST1321 SMH Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Brain RTOG 1071 SMH RTOG1071/N0577(CODEL): Phase III Intergroup Study of Radiotherapy with
Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
  RTOG 3503 SMH RTOG 3503 Phase II Trial of Optune® Plus Bevacizumab in Bevacizumab-
Refractory Recurrent Glioblastoma
  PI 70001 SMH A prospective pilot study of cognitive changes in patients receiving partial
brain radiation: development of a radiation dose-toxicity model for
neuroanatomic targets
  Alliance A221101 SMH A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) to Reduce Cancer-Related Fatigue in Patients with
High Grade Glioma
  NRG NRG-BN003 SMH NRG-BN003 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Breast RTOG 1304 Pluta NSABP 51_RTOG 1304: A Randomized Phase III Clinical Trial Evaluating
Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary
Gastrointestinal RTOG 848 SMH, HH RTOG 848: A Phase III Trial of Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
  RTOG 1112 SMH RTOG 1112: Phase III Study of Sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma
  NRG GI001 SMH NRG GI001 Randomized Phase III Study Of Focal Radiation Therapy For
Unresectable, Localized Intrahepatic Cholangiocarcinoma
  PI ULAB11068 SMH Analysis of Clinical Data and Lung Dose Using Volumetric Analysis in Patients Treated with Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma
  PI UGIP14107 SMH, HH Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer
Genitourinary NRG 0924 SMH, HH RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy
With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial
  Industry 56021927PCR 3003 SMH, HH Janssen: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of
JNJ-56021927 (ARN-509) in Subjects with High-risk, Localized or Locally
Advanced Prostate Cancer Receiving Treatment with Primary Radiation
Therapy
  DOD 59133 SMH Risk Prediction for Development of Adverse Effects Following Radiotherapy
for Prostate Cancer
  NRG GU002 SMH, HH NRG-GU002 Phase II-III Trial of Adjuvant Radiotherapy and Androgen
Deprivation Following Radical Prostatectomy With or Without Adjuvant
Docetaxel
Head and Neck RTOG 920 SMH, Sands A Phase III Study of Postop RT (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
  RTOG 1008 SMH, HH A Randomized Phase II Study of Adjuvant Concurrent Radiation and
Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant
Salivary Gland Tumors
  NRG HN001 SMH NRG HN001: Randomized Phase II and Phase III Studies of Individualized
Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Lung RTOG 538 SMH, HH RTOG 538/(CALGB 30610): Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Stage Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
  Alliance A081105 SMH A081105 ALCHEMIST EGFR + Randomized Study of Erlotinib vs
Observation in Patients with Completely Resected Epidermal Growth Factor
Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
  Alliance A151216 SMH, HH, PR, Sands ALCHEMIST Screening A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
  ECOG E4512 SMH ALCHEMIST ALK+ A Phase III Trial for Surgically Resected Early Stage Non-
Small Cell Lung Cancer: Crizotinib versus Observation for Patients with
Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
  ECOG EA5142 SMH Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized
Phase III Study of Nivolumab After Surgical Resection and Adjuvant
Chemotherapy in Non-Small Cell Lung Cancers
  NRG LU002 SMH NRG LU002: Maintenance Systemic Therapy versus Consolidative
Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic
Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A
Randomized Phase II/III trial.
Metastases from Breast NRG BR002 SMH BR002: A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Metastases to Brain RTOG 1119 SMH RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastases from HER2-positive Breast Cancer
Metastases to Multiple Organs NRG BR001 SMH BR001: A Phase I Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases